nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2014 | Non-Thematic Review

Emerging roles of regulatory T cells in tumour progression and metastasis

verfasst von: Elizabeth C. Halvorsen, Sahar M. Mahmoud, Kevin L. Bennewith

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The metastasis of cancer is a complex and life-threatening process that is only partially understood. Immune suppressive cells are recognized as important contributors to tumour progression and may also promote the development and growth of tumour metastases. Specifically, regulatory T cells (Tregs) have been found to promote primary tumour progression, and emerging pre-clinical data suggests that Tregs may promote metastasis and metastatic tumour growth. While the precise role that Tregs play in metastatic progression is understudied, recent findings have indicated that by suppressing innate and adaptive anti-tumour immunity, Tregs may shield tumour cells from immune detection, and thereby allow tumour cells to survive, proliferate and acquire characteristics that facilitate dissemination. This review will highlight our current understanding of Tregs in metastasis, including an overview of pre-clinical findings and discussion of clinical data regarding Tregs and therapeutic outcome. Evolving strategies to directly ablate Tregs or to inhibit their function will also be discussed. Improving our understanding of how Tregs may influence tumour metastasis may lead to novel treatments for metastatic cancer.

Beyer, M., & Schultze, J. L. (2006). Regulatory T cells in cancer. Blood, 108(3), 804–811.PubMed

Maizels, R. M., & Smith, K. A. (2011). Regulatory T cells in infection. Advances in Immunology, 112, 73–136.PubMed

Gershon, R. K., & Kondo, K. (1970). Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology, 18(5), 723–737.PubMedCentralPubMed

Berendt, M. J., & North, R. J. (1980). T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. Journal of Experimental Medicine, 151(1), 69–80.PubMed

Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155(3), 1151–1164.

Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics, 27(1), 20–21.PubMed

Williams, L. M., & Rudensky, A. Y. (2007). Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nature Immunology, 8(3), 277–284.PubMed

McMurchy, A. N., Bushell, A., Levings, M. K., & Wood, K. J. (2011). Moving to tolerance: clinical application of T regulatory cells. Seminars in Immunology, 23(4), 304–313.PubMed

Pacholczyk, R., & Kern, J. (2008). The T-cell receptor repertoire of regulatory T cells. Immunology, 125(4), 450–458.PubMedCentralPubMed

10.

Bilate, A. M., & Lafaille, J. J. (2012). Induced CD4⁺Foxp3⁺ regulatory T cells in immune tolerance. Annual Review of Immunology, 30, 733–758.PubMed

11.

Toker, A., Engelbert, D., Garg, G., Polansky, J. K., Floess, S., Miyao, T., et al. (2013). Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. Journal of Immunology, 190(7), 3180–3188.

12.

Shalev, I., Schmelzle, M., Robson, S. C., & Levy, G. (2011). Making sense of regulatory T cell suppressive function. Seminars in Immunology, 23(4), 282–292.PubMedCentralPubMed

13.

Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010). Foxp3⁺ regulatory T cells in the human immune system. Nature Reviews Immunology, 10(7), 490–500.PubMed

14.

Allan, S. E., Song-Zhao, G. X., Abraham, T., McMurchy, A. N., & Levings, M. K. (2008). Inducible reprogramming of human T cells into Treg cells by a conditionally active form of Foxp3. European Journal of Immunology, 38(12), 3282–3289.PubMed

15.

Gratz, I. K., & Campbell, D. J. (2014). Organ-specific and memory treg cells: specificity, development, function, and maintenance. Frontiers in Immunology, 5, 333.PubMedCentralPubMed

16.

Corthay, A. (2009). How do regulatory T cells work? Scandinavian Journal of Immunology, 70(4), 326–336.PubMedCentralPubMed

17.

Morlacchi, S., Dal Secco, V., Soldani, C., Glaichenhaus, N., Viola, A., & Sarukhan, A. (2011). Regulatory T cells target chemokine secretion by dendritic cells independently of their capacity to regulate T cell proliferation. Journal of Immunology, 186(12), 6807–6814.

18.

Yamaguchi, T., Wing, J. B., & Sakaguchi, S. (2011). Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Seminars in Immunology, 23(6), 424–430.PubMed

19.

Wright, G. P., Notley, C. A., Xue, S. A., Bendle, G. M., Holler, A., Schumacher, T. N., et al. (2009). Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences of the United States of America, 106(45), 19078–19083.PubMedCentralPubMed

20.

Facciabene, A., Motz, G. T., & Coukos, G. (2012). T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Research, 72(9), 2162–2171.PubMedCentralPubMed

21.

Mailloux, A. W., & Young, M. R. (2010). Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Critical Reviews in Immunology, 30(5), 435–447.PubMedCentralPubMed

22.

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 10(9), 942–949.PubMed

23.

Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., et al. (2009). Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research, 69(5), 2000–2009.PubMed

24.

Tan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J. Q., Hoffman, R. M., et al. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470(7335), 548–553.PubMedCentralPubMed

25.

Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475(7355), 226–230.PubMed

26.

Wei, S., Kryczek, I., Edwards, R. P., Zou, L., Szeliga, W., Banerjee, M., et al. (2007). Interleukin-2 administration alters the CD4⁺Foxp3⁺ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Research, 67(15), 7487–7494.PubMed

27.

Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., et al. (2007). Tumor evasion of the immune system by converting CD4⁺CD25⁻ T cells into CD4⁺CD25⁺ T regulatory cells: role of tumor-derived TGF-beta. Journal of Immunology, 178(5), 2883–2892.

28.

Valzasina, B., Piconese, S., Guiducci, C., & Colombo, M. P. (2006). Tumor-induced expansion of regulatory T cells by conversion of CD4⁺CD25⁻ lymphocytes is thymus and proliferation independent. Cancer Research, 66(8), 4488–4495.PubMed

29.

Elkord, E., Sharma, S., Burt, D. J., & Hawkins, R. E. (2011). Expanded subpopulation of FoxP3⁺ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clinical Immunology, 140(3), 218–222.PubMed

30.

Nizar, S., Meyer, B., Galustian, C., Kumar, D., & Dalgleish, A. (2010). T regulatory cells, the evolution of targeted immunotherapy. Biochimica et Biophysica Acta, 1806(1), 7–17.PubMed

31.

Mougiakakos, D., Johansson, C. C., & Kiessling, R. (2009). Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood, 113(15), 3542–3545.PubMed

32.

Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., et al. (2006). High numbers of tumor-infiltrating Foxp3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 108(9), 2957–2964.PubMed

33.

Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S., MacDougall, F., et al. (2006). Number of CD4⁺ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. Journal of Clinical Oncology, 24(31), 5052–5059.PubMed

34.

Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S. A., & Dirnhofer, S. (2008). Correlation of high numbers of intratumoral Foxp3⁺ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica, 93(2), 193–200.PubMed

35.

Polcher, M., Braun, M., Friedrichs, N., Rudlowski, C., Bercht, E., Fimmers, R., et al. (2010). Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunology, Immunotherapy, 59(6), 909–919.PubMed

36.

Wolf, D., Wolf, A. M., Rumpold, H., Fiegl, H., Zeimet, A. G., Muller-Holzner, E., et al. (2005). The expression of the regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer. Clinical Cancer Research, 11(23), 8326–8331.PubMed

37.

Chen, K. J., Zhou, L., Xie, H. Y., Ahmed, T. E., Feng, X. W., & Zheng, S. S. (2012). Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Medical Oncology, 29(3), 1817–1826.PubMed

38.

Gao, Q., Qiu, S. J., Fan, J., Zhou, J., Wang, X. Y., Xiao, Y. S., et al. (2007). Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. Journal of Clinical Oncology, 25(18), 2586–2593.PubMed

39.

Li, J. F., Chu, Y. W., Wang, G. M., Zhu, T. Y., Rong, R. M., Hou, J., et al. (2009). The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU International, 103(3), 399–405.PubMed

40.

Siddiqui, S. A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., et al. (2007). Tumor-infiltrating Foxp3-CD4⁺CD25⁺ T cells predict poor survival in renal cell carcinoma. Clinical Cancer Research, 13(7), 2075–2081.PubMed

41.

Hiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006). Prevalence of Foxp3⁺ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clinical Cancer Research, 12(18), 5423–5434.PubMed

42.

Mougiakakos, D., Johansson, C. C., Trocme, E., All-Ericsson, C., Economou, M. A., Larsson, O., et al. (2010). Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer, 116(9), 2224–2233.PubMed

43.

Brudvik, K. W., Henjum, K., Aandahl, E. M., Bjornbeth, B. A., & Tasken, K. (2012). Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunology, Immunotherapy, 61(7), 1045–1053.PubMed

44.

Shimizu, K., Nakata, M., Hirami, Y., Yukawa, T., Maeda, A., & Tanemoto, K. (2010). Tumor-infiltrating Foxp3⁺ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. Journal of Thoracic Oncology, 5(5), 585–590.PubMed

45.

Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., et al. (2010). Regulatory (Foxp3⁺) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. Journal of Immunotherapy, 33(4), 435–441.PubMed

46.

Ladoire, S., Martin, F., & Ghiringhelli, F. (2011). Prognostic role of Foxp3⁺ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunology, Immunotherapy, 60(7), 909–918.PubMed

47.

Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., et al. (2009). Tumor-infiltrating Foxp3⁺ T regulatory cells show strong prognostic significance in colorectal cancer. Journal of Clinical Oncology, 27(2), 186–192.PubMed

48.

Haas, M., Dimmler, A., Hohenberger, W., Grabenbauer, G. G., Niedobitek, G., & Distel, L. V. (2009). Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterology, 9, 65.PubMedCentralPubMed

49.

Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., et al. (2006). Prognostic value of tumor-infiltrating CD4⁺ T-cell subpopulations in head and neck cancers. Clinical Cancer Research, 12(2), 465–472.PubMed

50.

Bron, L., Jandus, C., Andrejevic-Blant, S., Speiser, D. E., Monnier, P., Romero, P., et al. (2013). Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. International Journal of Cancer, 132(3), E85–E93.

51.

Strauss, L., Bergmann, C., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007). The frequency and suppressor function of CD4⁺CD25highFoxp3⁺ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research, 13(21), 6301–6311.PubMed

52.

Chaudhary, B., Abd Al Samid, M., al-Ramadi, B. K., & Elkord, E. (2014). Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opinion on Biological Therapy, 14(7), 931–945.PubMed

53.

Zitvogel, L., Kepp, O., & Kroemer, G. (2011). Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews. Clinical Oncology, 8(3), 151–160.PubMed

54.

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annual Review of Immunology, 22, 329–360.PubMed

55.

Hori, S., Nomura, T., & Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299(5609), 1057–1061.PubMed

56.

Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., et al. (2009). Foxp3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Research, 69(9), 3995–4000.PubMed

57.

Roncador, G., Brown, P. J., Maestre, L., Hue, S., Martinez-Torrecuadrada, J. L., Ling, K. L., et al. (2005). Analysis of Foxp3 protein expression in human CD4⁺CD25⁺ regulatory T cells at the single-cell level. European Journal of Immunology, 35(6), 1681–1691.PubMed

58.

Hinz, S., Pagerols-Raluy, L., Oberg, H. H., Ammerpohl, O., Grussel, S., Sipos, B., et al. (2007). Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Research, 67(17), 8344–8350.PubMed

59.

Zuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., et al. (2007). Foxp3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell, 129(7), 1275–1286.PubMedCentralPubMed

60.

Triulzi, T., Tagliabue, E., Balsari, A., & Casalini, P. (2013). Foxp3 expression in tumor cells and implications for cancer progression. Journal of Cellular Physiology, 228(1), 30–35.PubMed

61.

Li, W., Wang, L., Katoh, H., Liu, R., Zheng, P., & Liu, Y. (2011). Identification of a tumor suppressor relay between the Foxp3 and the Hippo pathways in breast and prostate cancers. Cancer Research, 71(6), 2162–2171.PubMedCentralPubMed

62.

McInnes, N., Sadlon, T. J., Brown, C. Y., Pederson, S., Beyer, M., Schultze, J. L., et al. (2012). Foxp3 and Foxp3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene, 31(8), 1045–1054.PubMed

63.

Dimitrakopoulos, F. I., Papadaki, H., Antonacopoulou, A. G., Kottorou, A., Gotsis, A. D., Scopa, C., et al. (2011). Association of Foxp3 expression with non-small cell lung cancer. Anticancer Research, 31(5), 1677–1683.PubMed

64.

Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Menard, S., et al. (2009). Foxp3 expression and overall survival in breast cancer. Journal of Clinical Oncology, 27(11), 1746–1752.PubMed

65.

Winerdal, M. E., Marits, P., Winerdal, M., Hasan, M., Rosenblatt, R., Tolf, A., et al. (2011). Foxp3 and survival in urinary bladder cancer. BJU International, 108(10), 1672–1678.PubMed

66.

Xue, L., Lu, H. Q., He, J., Zhao, X. W., Zhong, L., Zhang, Z. Z., et al. (2010). Expression of Foxp3 in esophageal squamous cell carcinoma relating to the clinical data. Diseases of the Esophagus, 23(4), 340–346.PubMed

67.

Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., et al. (2009). Functional delineation and differentiation dynamics of human CD4⁺ T cells expressing the Foxp3 transcription factor. Immunity, 30(6), 899–911.PubMed

68.

Rech, A. J., Mick, R., Kaplan, D. E., Chang, K. M., Domchek, S. M., & Vonderheide, R. H. (2010). Homeostasis of peripheral Foxp3(+) CD4(+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 59(4), 599–607.PubMed

69.

Xu, L., Xu, W., Qiu, S., & Xiong, S. (2010). Enrichment of CCR6⁺Foxp3⁺ regulatory T cells in the tumor mass correlates with impaired CD8⁺ T cell function and poor prognosis of breast cancer. Clinical Immunology, 135(3), 466–475.PubMed

70.

Nishikawa, H., & Sakaguchi, S. (2014). Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 27, 1–7.PubMed

71.

Kryczek, I., Wu, K., Zhao, E., Wei, S., Vatan, L., Szeliga, W., et al. (2011). IL-17⁺ regulatory T cells in the microenvironments of chronic inflammation and cancer. Journal of Immunology, 186(7), 4388–4395.

72.

Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., et al. (2010). Generation and accumulation of immunosuppressive adenosine by human CD4⁺CD25highFoxp3⁺ regulatory T cells. Journal of Biological Chemistry, 285(10), 7176–7186.PubMedCentralPubMed

73.

Schuler, P. J., Schilling, B., Harasymczuk, M., Hoffmann, T. K., Johnson, J., Lang, S., et al. (2012). Phenotypic and functional characteristics of CD4⁺ CD39⁺ Foxp3⁺ and CD4⁺ CD39⁺ Foxp3neg T-cell subsets in cancer patients. European Journal of Immunology, 42(7), 1876–1885.PubMedCentralPubMed

74.

Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., et al. (2013). Anti-CCR4 mAb selectively depletes effector-type Foxp3⁺CD4⁺ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 110(44), 17945–17950.PubMedCentralPubMed

75.

Crome, S. Q., Clive, B., Wang, A. Y., Kang, C. Y., Chow, V., Yu, J., et al. (2010). Inflammatory effects of ex vivo human Th17 cells are suppressed by regulatory T cells. Journal of Immunology, 185(6), 3199–3208.

76.

Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology, 24(34), 5373–5380.PubMed

77.

Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of Immunology, 169(5), 2756–2761.

78.

Aruga, T., Suzuki, E., Saji, S., Horiguchi, S., Horiguchi, K., Sekine, S., et al. (2009). A low number of tumor-infiltrating Foxp3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncology Reports, 22(2), 273–278.PubMed

79.

Liu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G. A., Fan, Y., et al. (2011). CD8(+) cytotoxic T cell and Foxp3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Research and Treatment, 130(2), 645–655.PubMed

80.

Yan, M., Jene, N., Byrne, D., Millar, E. K., O’Toole, S. A., McNeil, C. M., et al. (2011). Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research, 13(2), R47.PubMedCentralPubMed

81.

West, N. R., Kost, S. E., Martin, S. D., Milne, K., Deleeuw, R. J., Nelson, B. H., et al. (2013). Tumour-infiltrating Foxp3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 108(1), 155–162.PubMedCentralPubMed

82.

de Kruijf, E. M., van Nes, J. G., Sajet, A., Tummers, Q. R., Putter, H., Osanto, S., et al. (2010). The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clinical Cancer Research, 16(4), 1272–1280.PubMed

83.

Mahmoud, S. M., Paish, E. C., Powe, D. G., Macmillan, R. D., Lee, A. H., Ellis, I. O., et al. (2011). An evaluation of the clinical significance of Foxp3⁺ infiltrating cells in human breast cancer. Breast Cancer Research and Treatment, 127(1), 99–108.PubMed

84.

Ali, H. R., Provenzano, E., Dawson, S. J., Blows, F. M., Liu, B., Shah, M., et al. (2014). Association between CD8⁺ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25(8), 1536–1543.PubMed

85.

Yang, Y., Guan, X., You, J. CLOPE: a fast and effective clustering algorithm for transactional data. In Proceedings of the eighth ACM SIGKDD international conference on knowledge discovery and data mining, Edmonton, Alberta, Canada, 2002 (pp. 682–687): ACM

86.

Mahmoud, S. M. (2011). Inflammation and immunosurveillance in breast Cancer [PhD thesis]. Nottingham, UK: The University of Nottingham. http://etheses.nottingham.ac.uk/1827/

87.

Ladoire, S., Arnould, L., Mignot, G., Coudert, B., Rebe, C., Chalmin, F., et al. (2011). Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 125(1), 65–72.PubMed

88.

Zuo, T., Liu, R., Zhang, H., Chang, X., Liu, Y., Wang, L., et al. (2007). Foxp3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. Journal of Clinical Investigation, 117(12), 3765–3773.PubMedCentralPubMed

89.

Douglass, S., Meeson, A. P., Overbeck-Zubrzycka, D., Brain, J. G., Bennett, M. R., Lamb, C. A., et al. (2014). Breast cancer metastasis: demonstration that Foxp3 regulates CXCR4 expression and the response to CXCL12. Journal of Pathology, 234 (1), 74–85.

90.

von Minckwitz, G., Untch, M., Blohmer, J. U., Costa, S. D., Eidtmann, H., Fasching, P. A., et al. (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology, 30(15), 1796–1804.

91.

Demir, L., Yigit, S., Ellidokuz, H., Erten, C., Somali, I., Kucukzeybek, Y., et al. (2013). Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral Foxp3⁺ Tregs. Clinical and Experimental Metastasis, 30(8), 1047–1062.PubMed

92.

Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., et al. (2008). Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3⁺ regulatory T cells. Clinical Cancer Research, 14(8), 2413–2420.PubMed

93.

Verma, C., Eremin, J. M., Robins, A., Bennett, A. J., Cowley, G. P., El-Sheemy, M. A., et al. (2013). Abnormal T regulatory cells (Tregs: Foxp3⁺, CTLA-4⁺), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal Treg profile with treatment and correlation of Treg levels with pathological response to NAC. Journal of Translational Medicine, 11, 16.PubMedCentralPubMed

94.

Decker, T., Fischer, G., Bucke, W., Bucke, P., Stotz, F., Gruneberger, A., et al. (2012). Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with HER-2/neu-positive early breast cancer. Journal of Cancer Research and Clinical Oncology, 138(11), 1945–1950.PubMed

95.

Lal, A., Chan, L., Devries, S., Chin, K., Scott, G. K., Benz, C. C., et al. (2013). Foxp3-positive regulatory T lymphocytes and epithelial Foxp3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Research and Treatment, 139(2), 381–390.PubMed

96.

Recchia, F., Candeloro, G., Necozione, S., Desideri, G., Cesta, A., Recchia, L., et al. (2013). Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer. Oncology Letters, 5(4), 1117–1122.PubMedCentralPubMed

97.

Takenaka, M., Seki, N., Toh, U., Hattori, S., Kawahara, A., Yamaguchi, T., et al. (2013). Foxp3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Molecular and Clinical Oncology, 1(4), 625–632.PubMedCentralPubMed

98.

Zhou, S., Xu, S., Tao, H., Zhen, Z., Chen, G., Zhang, Z., et al. (2013). CCR7 expression and intratumoral Foxp3⁺ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PloS One, 8(9), e74430.PubMedCentralPubMed

99.

Huen, N. Y., Pang, A. L., Tucker, J. A., Lee, T. L., Vergati, M., Jochems, C., et al. (2013). Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. International Journal of Cancer, 133(2), 373–382.

100.

Kang, M. J., Kim, K. M., Bae, J. S., Park, H. S., Lee, H., Chung, M. J., et al. (2013). Tumor-infiltrating PD1-positive lymphocytes and Foxp3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Translational Oncology, 6(3), 282–289.PubMedCentralPubMed

101.

French, J. D., Kotnis, G. R., Said, S., Raeburn, C. D., McIntyre, R. C., Jr., Klopper, J. P., et al. (2012). Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 97(6), E934–E943.PubMedCentralPubMed

102.

Fu, H. Y., Li, C., Yang, W., Gai, X. D., Jia, T., Lei, Y. M., et al. (2013). Foxp3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochemica, 115(2), 151–157.PubMed

103.

Efimova, O. V., & Kelley, T. W. (2009). Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway. BMC Immunology, 10, 59.PubMedCentralPubMed

104.

Garin, M. I., Chu, C. C., Golshayan, D., Cernuda-Morollon, E., Wait, R., & Lechler, R. I. (2007). Galectin-1: a key effector of regulation mediated by CD4⁺CD25⁺ T cells. Blood, 109(5), 2058–2065.PubMed

105.

Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., et al. (2007). Expression of ectonucleotidase CD39 by Foxp3⁺ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 110(4), 1225–1232.PubMed

106.

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., et al. (2013). Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science Translational Medicine, 5(200), 200ra116.PubMedCentralPubMed

107.

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. (2008). CTLA-4 control over Foxp3⁺ regulatory T cell function. Science, 322(5899), 271–275.PubMed

108.

Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013). Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. Journal of Experimental Medicine, 210(11), 2435–2466.PubMedCentralPubMed

109.

Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., et al. (2010). LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. Journal of Immunology, 184(11), 6545–6551.

110.

Delgoffe, G. M., Woo, S. R., Turnis, M. E., Gravano, D. M., Guy, C., Overacre, A. E., et al. (2013). Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature, 501(7466), 252–256.PubMed

111.

Facciabene, A., Santoro, S., & Coukos, G. (2012). Know thy enemy: why are tumor-infiltrating regulatory T cells so deleterious? Oncoimmunology, 1(4), 575–577.PubMedCentralPubMed

112.

Whiteside, T. L. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27(45), 5904–5912.PubMedCentralPubMed

113.

Karavitis, J., Hix, L. M., Shi, Y. H., Schultz, R. F., Khazaie, K., & Zhang, M. (2012). Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PloS One, 7(9), e46342.PubMedCentralPubMed

114.

Kudo-Saito, C., Shirako, H., Ohike, M., Tsukamoto, N., & Kawakami, Y. (2013). CCL2 is critical for immunosuppression to promote cancer metastasis. Clinical and Experimental Metastasis, 30(4), 393–405.PubMed

115.

Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., et al. (2012). Neuropilin 1 deficiency on CD4⁺Foxp3⁺ regulatory T cells impairs mouse melanoma growth. Journal of Experimental Medicine, 209(11), 2001–2016.PubMedCentralPubMed

116.

Wada, J., Suzuki, H., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., et al. (2009). The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Research, 29(3), 881–888.PubMed

117.

Gupta, S., Joshi, K., Wig, J. D., & Arora, S. K. (2007). Intratumoral Foxp3 expression in infiltrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. Acta Oncologica, 46(6), 792–797.PubMed

118.

Boyce, B. F., & Xing, L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research and Therapy, 9(Suppl 1), S1.PubMedCentralPubMed

119.

Faghih, Z., Erfani, N., Haghshenas, M. R., Safaei, A., Talei, A. R., & Ghaderi, A. (2014). Immune profiles of CD4⁺ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunology Letters, 158(1–2), 57–65.PubMed

120.

Kashimura, S., Saze, Z., Terashima, M., Soeta, N., Ohtani, S., Osuka, F., et al. (2012). CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer. Gastric Cancer, 15(2), 144–153.PubMed

121.

Mansfield, A. S., Heikkila, P. S., Vaara, A. T., von Smitten, K. A., Vakkila, J. M., & Leidenius, M. H. (2009). Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 9, 231.PubMedCentralPubMed

122.

Tsiatas, M. L., Gyftaki, R., Liacos, C., Politi, E., Rodolakis, A., Dimopoulos, M. A., et al. (2009). Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. International Journal of Gynecological Cancer, 19(8), 1329–1334.PubMed

123.

Abadi, Y. M., Jeon, H., Ohaegbulam, K. C., Scandiuzzi, L., Ghosh, K., Hofmeyer, K. A., et al. (2013). Host b7x promotes pulmonary metastasis of breast cancer. Journal of Immunology, 190(7), 3806–3814.

124.

Biragyn, A., Bodogai, M., Olkhanud, P. B., Denny-Brown, S. R., Puri, N., Ayukawa, K., et al. (2013). Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4⁺ Tregs. Journal of Immunotherapy, 36(4), 258–267.PubMedCentralPubMed

125.

Chopra, M., Riedel, S. S., Biehl, M., Krieger, S., von Krosigk, V., Bauerlein, C. A., et al. (2013). Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis, 34(6), 1296–1303.PubMed

126.

Dalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Mendez-Huergo, S. P., et al. (2013). Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Research, 73(3), 1107–1117.PubMed

127.

Ghochikyan, A., Davtyan, A., Hovakimyan, A., Davtyan, H., Poghosyan, A., Bagaev, A., et al. (2014). Primary 4T1 tumor resection provides critical “window of opportunity” for immunotherapy. Clinical and Experimental Metastasis, 31(2), 185–198.PubMed

128.

Kim, P. S., Jochems, C., Grenga, I., Donahue, R. N., Tsang, K. Y., Gulley, J. L., et al. (2014). Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. Journal of Immunology, 192(6), 2622–2633.

129.

Mandl, S. J., Rountree, R. B., Dalpozzo, K., Do, L., Lombardo, J. R., Schoonmaker, P. L., et al. (2012). Immunotherapy with MVA-BN(R)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunology, Immunotherapy, 61(1), 19–29.PubMedCentralPubMed

130.

Olkhanud, P. B., Baatar, D., Bodogai, M., Hakim, F., Gress, R., Anderson, R. L., et al. (2009). Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Research, 69(14), 5996–6004.PubMedCentralPubMed

131.

Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., et al. (2011). Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Research, 71(10), 3505–3515.PubMedCentralPubMed

132.

Tanikawa, T., Wilke, C. M., Kryczek, I., Chen, G. Y., Kao, J., Nunez, G., et al. (2012). Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Research, 72(2), 420–429.PubMedCentralPubMed

133.

Lee-Chang, C., Bodogai, M., Martin-Montalvo, A., Wejksza, K., Sanghvi, M., Moaddel, R., et al. (2013). Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. Journal of Immunology, 191(8), 4141–4151.

134.

Vadrevu, S. K., Chintala, N. K., Sharma, S. K., Sharma, P., Cleveland, C., Riediger, L., et al. (2014). Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Research, 74(13), 3454–3465.PubMed

135.

Weiss, J. M., Subleski, J. J., Back, T., Chen, X., Watkins, S. K., Yagita, H., et al. (2014). Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy. Journal of Immunology, 192(12), 5821–5829.

136.

Kim, R., Emi, M., & Tanabe, K. (2007). Cancer immunoediting from immune surveillance to immune escape. Immunology, 121(1), 1–14.PubMedCentralPubMed

137.

Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014). Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal of Immunotherapy of Cancer, 2, 3.

138.

Byrne, W. L., Mills, K. H., Lederer, J. A., & O’Sullivan, G. C. (2011). Targeting regulatory T cells in cancer. Cancer Research, 71(22), 6915–6920.PubMed

139.

von Boehmer, H., & Daniel, C. (2013). Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nature Reviews Drug Discovery, 12(1), 51–63.

140.

Kozawa, E., Sugiura, H., Wasa, J., Kohyama, K., Yamada, K., Nishioka, A., et al. (2010). Suppression of tumour metastasis in a murine osteosarcoma model with anti-CD25 monoclonal antibody treatment. Anticancer Research, 30(12), 5019–5022.PubMed

141.

Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013). Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clinical Cancer Research, 19(20), 5626–5635.PubMed

142.

Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., et al. (2012). Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunology, Immunotherapy, 61(3), 353–362.PubMed

143.

Kaji, W., Tanaka, S., Tsukimoto, M., & Kojima, S. (2014). Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells. Journal of Toxicological Sciences, 39(2), 191–198.PubMed

144.

Li, C. X., Wong, B. L., Ling, C. C., Ma, Y. Y., Shao, Y., Geng, W., et al. (2014). A novel oxygen carrier “YQ23” suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells. BMC Cancer, 14(1), 293.PubMedCentralPubMed

145.

Pohla, H., Buchner, A., Stadlbauer, B., Frankenberger, B., Stevanovic, S., Walter, S., et al. (2012). High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Molecular Medicine, 18, 1499–1508.PubMedCentral

146.

Shahabi, V., Seavey, M. M., Maciag, P. C., Rivera, S., & Wallecha, A. (2011). Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of HER2/neu-overexpressing cancers in human. Cancer Gene Therapy, 18(1), 53–62.PubMed

147.

Maciag, P. C., Radulovic, S., & Rothman, J. (2009). The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine, 27(30), 3975–3983.PubMed

148.

Wallecha, A., Singh, R., & Malinina, I. (2013). Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. Journal of Immunotherapy, 36(9), 468–476.PubMed

149.

Audia, S., Nicolas, A., Cathelin, D., Larmonier, N., Ferrand, C., Foucher, P., et al. (2007). Increase of CD4⁺CD25⁺ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4⁺CD25⁺ T lymphocytes. Clinical and Experimental Immunology, 150(3), 523–530.PubMedCentralPubMed

150.

Emmenegger, U., Francia, G., Chow, A., Shaked, Y., Kouri, A., Man, S., et al. (2011). Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia, 13(1), 40–48.PubMedCentralPubMed

151.

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. Journal of Experimental Medicine, 210(9), 1695–1710.PubMedCentralPubMed

152.

Galon, J., Pages, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., et al. (2012). Cancer classification using the immunoscore: a worldwide task force. Journal of Translational Medicine, 10, 205.PubMedCentralPubMed

153.

Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., et al. (2014). Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours. Journal of Pathology, 232(2), 199–209.PubMed

154.

Gonzalez, L., Strbo, N., & Podack, E. R. (2013). Humanized mice: novel model for studying mechanisms of human immune-based therapies. Immunologic Research, 57(1–3), 326–334.PubMed

155.

Budiu, R. A., Elishaev, E., Brozick, J., Lee, M., Edwards, R. P., Kalinski, P., et al. (2013). Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene, 32(32), 3664–3675.PubMedCentralPubMed

156.

Drennan, S., Stafford, N. D., Greenman, J., & Green, V. L. (2013). Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology, 140(3), 335–343.PubMedCentralPubMed

157.

Schneider, T., Kimpfler, S., Warth, A., Schnabel, P. A., Dienemann, H., Schadendorf, D., et al. (2011). Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. Journal of Thoracic Oncology, 6(3), 432–438.PubMed

Titel: Emerging roles of regulatory T cells in tumour progression and metastasis
verfasst von: Elizabeth C. Halvorsen
Sahar M. Mahmoud
Kevin L. Bennewith
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9529-x

Springer Medizin

Emerging roles of regulatory T cells in tumour progression and metastasis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine

Significance of MTA1 in the molecular characterization of osteosarcoma

MTA1—a stress response protein: a master regulator of gene expression and cancer cell behavior

Subcellular localization of MTA proteins in normal and cancer cells

Function and regulation of MTA1 and MTA3 in malignancies of the female reproductive system

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie